Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 8, 2019, discloses preliminary unaudited financial results for Altimmune, Inc. for the fiscal year ended December 31, 2018. The company is a biopharmaceutical firm focused on developing novel therapeutics. All per-share amounts reflect a 1-for-30 reverse stock split executed in September 2018.
Key Financial Metrics
| Metric | Value (Year Ended Dec 31, 2018) |
|---|---|
| Revenue | $10.0 million to $10.5 million |
| Total Operating Expenses | $53.0 million to $53.5 million |
| Net Loss | ($38.8) million to ($39.8) million |
| Net Loss Attributed to Common Stockholders | ($41.7) million to ($42.7) million |
| Net Loss Per Share (Basic and Diluted) | ($14.87) to ($15.23) |
| Cash, Cash Equivalents, and Restricted Cash | $34.4 million |
| Working Capital | $34.8 million |
| Total Assets | $54.8 million |
| Total Long-Term Liabilities | $1.9 million |
| Total Stockholders' Equity | $48.3 million |
Material Changes and Unusual Items
The filing highlights a significant potential impairment charge related to In-Process Research and Development (IPR&D) assets. As of September 30, 2018, the company held net intangible assets of $38.4 million. Due to a continued decline in stock price and a strategic review of the development pipeline under new leadership, management identified an impairment indicator.
While the quantitative impairment test was not complete at the time of filing, the company expects to record an IPR&D impairment charge in the range of $23.5 million to $25.5 million. This charge is a primary driver of the reported net loss.
Outlook and Management Commentary
Management notes that the financial results are preliminary and unaudited. Actual results may differ upon finalization of financial closing procedures. The filing references a December 13, 2018 press release (Exhibit 99.1) regarding updates to clinical programs and plans to expand the pipeline, though specific future guidance or revenue projections are not provided in this text.
Investor Verification Checklist
- Verify the final amount of the IPR&D impairment charge once the quantitative test is completed.
- Confirm the finalized audited financial statements for the year ended December 31, 2018, to reconcile with these preliminary estimates.
- Review the December 13, 2018 press release (Exhibit 99.1) for details on clinical program updates and pipeline expansion strategies.
- Monitor cash burn rates given the net loss range of approximately $39 million against cash reserves of $34.4 million.